FDA's provisional pathway for generative AI devices exposes a verification gap that output benchmarks and existing life cycle rules were not built to close.
FDA's Lifecycle Bet on GenAI-Enabled Devices
FDA is easing premarket friction for AI-enabled devices while shifting the real compliance burden to post-market monitoring that current guidance cannot yet catch.
